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Abstract
Background: Escherichia coli is the most common pathogen causing Urinary Tract Infections (UTI). Data from the
current National Surveillance program in Denmark (DANMAP) may not accurately represent the prevalence of
resistant E. coli in primary care, because only urine samples from complicated cases may be forwarded to the
microbiological departments at hospitals for diagnostic examination. The aim of this study was to assess the
prevalence of resistant E. coli to the most commonly used antimicrobial agents in primary care in a consecutive
sample of patients from general practice.
Methods: Observational study carried out from December 2014 to December 2015. Thirty-nine general practices
from The Capital Region of Denmark included adult patients with urinary tract symptoms and suspected UTI. All
urine samples were sent to the central laboratory Statens Serum Institut (SSI). Significant bacteriuria was interpreted
according to the European Urinalysis Standards. Susceptibility testing was performed and interpreted according to
the European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards.
Results: From the 39 general practices 505 patients were recruited. Completed data were obtained from 485 (96%)
patients. According to the European Urinalysis Standards, 261 (54%) patients had positive bacteriuria. The most
common uropathogen in patients with uncomplicated (uUTI) and complicated (cUTI) urinary tract infection was E.
coli 105 (69%) and 76 (70%), respectively. Eighty-two (45%) of 181 E. coli isolates were resistant to at least one of the
tested antibiotics and 50 out of 82 isolates were resistant to two or more antimicrobial agents. The highest
resistance-rate was found against ampicillin 34% (95% CI 24;42) in uUTI and 36% (24;46) in cUTI. There were no
differences in the distribution of resistance between uncomplicated and complicated cases. The prevalence of
resistance was similar to the one reported in DANMAP 2014.
Conclusion: In E. coli from uUTI there is high resistance rates to antimicrobial agents commonly used in primary
care. There was no difference in the distribution of resistant E. coli in suspected uUTI vs cUTI. In Denmark, data from
the National Surveillance program DANMAP can guide the decision for choice of antibiotic in patients with
suspected UTI seeking care in primary care.
Trial registration: ClinicalTrials.gov NCT02249273.
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Background
Antimicrobial resistance is one of the most important
threats to human health [1]. Multiple surveillance pro-
grams have been launched worldwide to monitor the
spread of resistant strains in community acquired and
nosocomial infections [2, 3].
Urinary tract infection (UTI) is the second most com-
mon bacterial infection managed in primary care [4, 5]
and Escherichia coli is the most common pathogen caus-
ing UTI [6, 7]. E. coli resistant to antibiotics is on the
rise, with great variation across regions [8, 9].
Experts recommend [10, 11] that choice of antibiotics in
patients with suspected complicated UTI should be based
on the results of a urine culture and susceptibility test,
while the choice of antibiotics in patients with suspected
uncomplicated UTI should be based on up-to-date sur-
veillance data of patients from primary care. Thus, pro-
spective surveillance of resistant patterns of uropathogens
isolated from all patients attending primary care is crucial
for guiding first and second line antibiotic selection.
Previous studies have suggested a systematic bias in sur-
veillance data because uncomplicated UTIs (uUTI) are un-
derrepresented, leading to an overestimation of resistance
rates in primary care [12, 13]. This is problematic because
general practitioners (GPs) need an accurate knowledge of
the prevalence of resistance to the most commonly used
antibiotics in primary care in order to make an appropriate
treatment decision (i.e. choosing the right antibiotic).
In Denmark, the DANMAP programme is used for
surveillance of antimicrobial consumption and anti-
microbial resistance in bacteria from animals, food and
humans [2]. DANMAP reports the prevalence of resist-
ance for bacteria from clinical samples analyzed at the
departments of clinical microbiology in Denmark. Part
of the urine samples analyzed at the microbiology de-
partments come from general practice.
The inferred prevalence of resistant strains in primary
care may suffer from selection bias as GPs may predom-
inantly send urine samples to culture in patients with
complicated UTI or treatment failure.
In this paper, we report the results of a study aiming
to assess the prevalence of resistant E. coli to the most
commonly used antimicrobial agents in Denmark in pa-
tients with suspected (both complicated and uncompli-
cated) UTI seeking care at primary care level.
Methods
Study design
Prospective observational study carried out from December
2014 to December 2015.
Participants
Five-hundred practices from The Capital Region of
Denmark were randomly invited to participate. Thirty-nine
practices accepted to consecutively recruit patients with the
following characteristics: i.) inclusion criteria: Adult patients
(i.e. > 18 years of age) seeking care in general practice
during office hours with dysuria and/or urinary frequency
as the main reason for consultation, and in which GPs
suspected a UTI; ii.) exclusion criteria: a) Currently taking
antibiotics, b) Inability to provide a urine sample, c)
Inability to sign an informed consent, d) Previous participa-
tion in this study.
Data collection
The day of the index consultation, all patients provided
10 mL of urine, which was sent to Statens Serum Institut
(SSI). The urine sample was preserved in boric acid and
sent by certified post the same day of the consultation.
Culture and susceptibility testing at the reference
laboratory
At SSI, the culture was analyzed by a medical laboratory
scientist, who had no information about the clinical his-
tory of the patient. A positive culture was defined as
growth of ≥103 Colony Forming Unit per milliliter
(CFU/mL) for E. coli according to the European Urinaly-
sis Standards [14].
Aerobic urine culture was carried out with 1 μL on
Blood agar plate and “Blue” agar plate (SSI Diagnostics;
Hillerød, Denmark) and 100 μL on ESBL chromogenic
culture media (Brilliance ESBL AGAR; Oxoid, UK).
ESBL plates were examined after one day of incubation
and read according to the colour chart provided by the
manufacturer. Phenotypic confirmation of ESBL produc-
tion was performed by the Total ESBL Confirm Kit
98,014 (Rosco Diagnostics, Taastrup, Denmark).
Susceptibility testing was performed and interpreted
according to EUCAST standards [15] on Mueller-Hinton
agar plates using Neo-Sensitabs (Sulfamethoxazole, tri-
methoprim, ampicillin, amoxicillin-clavulanic acid, cef-
podoxime, ciprofloxacin, nitrofurantoin and mecillinam
(Rosco Diagnostics).
Data analysis
We considered UTI as uncomplicated if the patient was a
non-pregnant woman, under 65-year old without reported
co-morbidity and assessed by the nurse or GP as not having
an acute complicated cystitis or suspected pyelonephritis.
In contrast, we considered UTI as complicated if the pa-
tient was a man, a pregnant woman, a woman 65-year or
older or with a reported co-morbidity or assessed by the
nurse or GP to have complicated cystitis or pyelonephritis.
The proportions of susceptible and resistant E. coli isolates
were compared between uncomplicated and complicated
UTI. Proportion of resistant E. coli isolates in our study was
compared to the proportion of resistant E. coli isolates from
primary healthcare from the National surveillance program
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DANMAP 2014. Significance of the differences between the
independent samples were performed by using the Pearson’s
Chi-Square test (alpha 5%; CI 95%) and Fisher exact test
when appropriate. Descriptive analyses were performed
using SAS software, Version 9.3 of the SAS System for
Windows 7. Copyright (c) 2002–2010 by SAS Institute Inc.,
Cary, NC, USA.
Results
Baseline characteristics
From the 39 practices, 505 patients were recruited. There
was completed information for 485 (96%) of the patients,
from which 261 (54%) had positive bacteriuria. Of the 261
cases, 152 (58%) were classified as uncomplicated UTI and
109 as complicated UTI. The most common uropathogen
in uncomplicated and complicated cases was E. coli 105
(69%) and 76 (70%), respectively - Fig. 1.
Antimicrobial resistance for E. coli isolates
Eighty-two (45%) of the 181 E. coli isolates were resistant
to at least one of the tested antimicrobial agents. Fifty
(28%) of the 181 E. coli isolates were resistant to more
than one antimicrobial agent. The distribution of resist-
ance for the tested antimicrobial agents was not signifi-
cantly different for the uncomplicated and complicated
cases - Fig. 2 and Additional file 1: Table S1.
The highest resistance rates were found for ampicillin:
34% (95% CI 24;42) of the E. coli from uncomplicated cases
and 36% (95% CI 24;46) of the E. coli from complicated
cases. It was followed by sulfamethoxazole: 31%, (95% CI
21;39) of the E. coli from uncomplicated cases and 24%
(95% CI 14;33) of the E. coli from complicated cases. Resist-
ance to pivmecillinam (first line antibiotic in Denmark) was
1% (95% CI 0;5) in E. coli from uUTI and 9% (95% CI 2;15)
from E. coli from cUTI. Resistance to third generation
cephalosporins and clavulanate (i.e. ESBL-resistance test)
was found in 6% (95% CI 1;10) of E. coli from uUTI and 3%
(95% CI 0;9) of E.coli from cUTI. None of the tested E. coli
isolates were resistant to nitrofurantoin – Table 1 and
Additional file 1: Table S2.
The differences between the resistance rates of E. coli
isolates from the study population and DANMAP 2014
were lower than 10% across all antibiotics, for which com-
parison was available. No single difference was statistically
significant. – Table 2 and Additional file 1: Table S2.
Discussion
Summary of main finding
This study shows that in uncomplicated cases there was
high resistance to antibiotics commonly used in primary
Fig. 1 Flow chart of the study population
Fig. 2 Distribution of susceptible and resistant E. coli isolates in
uncomplicated and complicated cases
Table 1 Resistance rates among E. coli isolates from patients
seeking care in primary care
Uncomplicated Complicated
n = 105 n = 76
Ampicillin 34% (24;42) 36% (24;46)
Sulfamethoxazole 31% (21;39) 24% (14;33)
Trimethoprim 23% (14;30) 17% (8;25)
Pivmecillinam 1% (0;5) 9% (2;15)
Ciprofloxacin 8% (2;12) 8%(1;14)
Nitrofurantoin 0 0
3rd gen. Cephalosporins + clavulanatea 6% (1;10) 3% (0;9)
aESBL status tested with combinations of the third generation cephalosporins
(Cefotaxime, Ceftazidime) and clavulanate
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care in Denmark. There was no statistically and clinically
significant difference in the distribution of resistant E.
coli, in suspected uncomplicated vs complicated cases.
Data from the National Surveillance program (DAN-
MAP 2014) can be used to guide the selection of first
and second line antibiotics to treat UTI in primary care
in Denmark.
Strengths and limitations
The pragmatic design of the study enabled the inclusion
of a wide variety of patients seeking care in primary care
due to urinary tract symptoms, thus uncomplicated and
complicated cases were equally likely to be included in the
study. It maximized generalizability to the patient popula-
tion seeking care in primary care settings in Denmark.
Furthermore, all patients had a urine culture inter-
preted at the same reference laboratory. The laboratory
technician had no access to clinical data. It minimized
the risk for review bias and inter-observer variability.
The main limitation of our study is the small sample
size resulting in lack of power to counteract the type II
error (i.e. accepting the null hypothesis of lack of differ-
ence, when there is a difference between the groups).
Nonetheless, the results of this study should be inter-
preted considering clinically relevant differences rather
than statistically significant differences.
For example, in DANMAP 2014 the resistance rate of
E. coli isolates to Sulfamethoxazole was 32%, while in
our study it was 28%. The difference between estimates
was not statistically significant and is not clinically rele-
vant too. The Infectious Disease Society of America
(IDSA) recommends that resistance rates above 20% is
the threshold at which sulfamethoxazole is no longer
recommended for empirical treatment [10].
Another example is the lower percentage of E.coli iso-
lates from the uUTI group resistant to pivmecillinam in
comparison to the cUTI group. Due to the small sample
size, we cannot rule out that the difference in the point
estimate was caused by chance.
Another limitation was that we relied on GPs judgment as
part of the operationalization of the uncomplicated versus
complicated variable. Thus, we cannot rule out that some pa-
tients may have been miss-classified as having uncomplicated
UTI by their GP. Currently, there is no agreement about the
criteria of classifying a patient as a uUTI or cUTI [16]. We
chose to take into consideration the GPs’ assessment because
it reflects more accurately the challenges for classifying
patients as uUTI and cUTI during everyday practice.
Comparison with other studies
The distribution of resistant E. coli in uncomplicated cases
is similar to the distribution reported in other studies from
Greece, Germany, Austria, Sweden, Portugal and the
United Kingdom, in which ampicillin has the highest resist-
ance and nitrofurantoin the lowest resistance rate [13, 17–
20]. It confirms that E. coli resistant to antibiotics com-
monly used in primary care is an increasing problem, even
in low prevalence settings such as the Danish context.
ESBL-producing E. coli was found in both uncompli-
cated and complicated cases seeking care at primary care
level. Previous studies have already pointed out that ESBL-
producing E. coli strains have the potential for spread be-
yond the hospital environment [21, 22]. Studies carried
out in China [23] and Spain [24] have shown the constant
increase of healthy carriers colonized with ESBL-
producing E. coli. Thus, treating community-acquired
urinary tract infections caused by ESBL-producing E. coli
is a growing problem to be dealt with at primary care level
as the therapeutic options are limited [25].
Relevance
In Denmark, there are different guidelines made by dif-
ferent health authorities [26–28]. All guidelines agree on
recommending pivmecillinam and sulfametizol as the
first line options in patients with suspected uncompli-
cated UTI. All agree on pivmecillinam as first line op-
tions in patients with suspected complicated UTI, while
only two suggest trimethroprim as an option too.
IDSA recommends that the selection of empirical anti-
biotics takes into consideration that resistance rates
should not exceed 10% for fluoroquinolones and 20% for
trimethoprim-sulfamethoxazole [10].
Based on the results of our study pivmecillinam is a good
first option, while the routine use of sulfamethizol needs to
be re-considered. In other countries, nitrofurantoin has
started to gain importance as part of the first line antibiotics
for the management of UTIs in primary care [10, 11]. A re-
cent systematic reviews [29] about the efficacy and toxicity
of short-term use (i.e. <14 days) of nitrofurantoin reported
no differences in the rates for adverse events when com-
pared to other antimicrobial agents and did not report
cases of pulmonary fibrosis and hepatotoxicity.
Table 2 Comparison of resistance rates for E. coli between the
National Surveillance program DANMAP and our study
DANMAP 2014 Our studya p-value
Ampicillin 39% 34% 0.19
Sulfamethoxazole 32% 28% 0.2
Trimethoprim N/A 20% N/A
Pivmecillinam 5% 4% 0.74
Ciprofloxacin 9% 8% 0.5
Nitrofurantoin N/A 0 N/A
3rd gen. Cephalosporins
+ clavulanateb
4% 4% 0.96
N/A no data from the National Surveillance program DANMAP 2014
aUncomplicated and complicated cases
bESBL- resistant E. coli
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Another alternative is Fosfomicyn [30]. It gives good
bacterial coverage with low toxicity and limited effect in
fecal flora, although it has low efficacy against Staphylo-
coccus saprophyticus. A systematic review reported fewer
adverse effect of fosfomicyn in pregnant women in com-
parison to other antibiotics used in primary care [31].
However, fosfomicyn is not licensed for use in Denmark;
hence, it was not included for assessment in this study.
Conclusion
Antimicrobial resistance is a rising problem that do not
belong exclusively to patients attended in secondary care
or complicated cases seen in primary care. In uncompli-
cated cases, there were high resistance rates to antibi-
otics commonly used in primary care. In Denmark, the
National Surveillance program DANMAP can guide the
decision for choice of antimicrobial agents in patients
with suspected UTI seeking care in primary care.
Additional file
Additional file 1: Table S1. Distribution of susceptible and resistant E. coli
isolates in uncomplicated and complicated cases. Table S2. Number of
resistant E.coli isolates in uncomplicated and complicated cases. (DOCX 19 kb)
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